BioSpace News Archive

Microvi was founded in 2008 by Dr. Fatemeh Shirazi, CEO and CTO.

Nationwide provider of precision health services expands to Lutz, Florida.

DotLab, a personalized medicine company for women’s health, announced today that it has secured $10 million in Series A funding.

Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for LYNPARZA® (Olaparib) for first line maintenance therapy in BRCA-mutated advanced ovarian cancer. FoundationOne CDx is an FDA-approved comprehensive genomic profiling (CGP) test for all solid tumors that incorporates multiple companion diagnostics.

Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the publication of a manuscript in Stem Cells Translational Medicine describing the results of an open label Phase 1 clinical trial evaluating the feasibility and safety of transplantation of its lead stem cell asset, NSI-566, for the treatment of motor deficits due to ischemic stroke.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter Fiscal 2019 on Thursday, August 1, 2019, prior to the opening of trading on the New York Stock Exchange.

ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced the appointment of Dr. Elizabeth Garner as its new Chief Medical Officer and member of the company’s Executive Committee, effective 15 July 2019

Sigma Chi International Fraternity announced a new $20-million pledge to Huntsman Cancer Foundation, dedicated to and used for women’s cancer research, treatment and wellness at Huntsman Cancer Institute.

Boston Biomedical, Inc. announced that the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma will be discontinued due to futility.